viral
respiratori
tract
infect
rti
common
caus
mild
ill
abstract
immunocompet
children
adult
occasion
signific
morbid
mortal
young
old
infirm
howev
recipi
solid
organ
transplant
sot
haematopoiet
stem
cell
transplant
hsct
markedli
increas
risk
signific
morbid
mortal
infect
infect
gener
acquir
transmiss
larg
respiratori
droplet
nosocomi
origin
mani
document
outbreak
specialis
transplant
unit
typic
infect
begin
upper
rti
cough
rhinorrhoea
predomin
mani
resolv
stage
immunocompromis
patient
typic
closer
time
sot
hsct
may
develop
progress
infect
lower
rti
pneumonia
common
rti
pathogen
influenza
virus
parainfluenza
virus
respiratori
syncyti
virus
newer
polymeras
chain
reactionbas
diagnost
strategi
sensit
previou
assay
allow
rapid
accur
diagnos
infect
newer
assay
may
also
detect
emerg
pathogen
signific
one
human
metapneumoviru
diagnost
techniqu
advanc
significantli
past
decad
well
establish
effect
specif
treatment
infect
remain
elus
epidemiolog
clinic
present
diagnosi
treatment
common
viral
rti
sot
hsct
recipi
review
recommend
present
base
thorough
review
recent
literatur
respiratori
virus
common
caus
mild
taliti
rate
incid
rate
rang
selflimit
upper
respiratori
tract
infect
surveil
studi
hsct
recipi
ti
immunocompet
individu
vari
retrospect
studi
hsct
recipitheir
season
frequenc
tend
infect
ent
lung
transplant
recipi
children
often
adult
symptomat
symptomat
diseas
surveil
studi
diseas
may
persist
day
week
healthi
hospitalis
patient
leukaemia
hospitaloutpati
signific
morbid
mortal
unis
clinic
patient
recent
hsct
md
common
anderson
cancer
center
report
pain
immunocompromis
patient
includ
tient
progress
viral
urti
pneumohaematopoiet
stem
cell
transplant
hsct
nia
mortal
rate
associ
respiratori
solid
organ
transplant
sot
recipi
respiratori
virus
vari
literatur
earlier
case
virus
may
either
commun
acquir
hospiseri
hospitalis
hsct
sot
recipi
tal
acquir
associ
longer
period
lrti
report
high
mortal
rate
infect
increas
progress
lower
respirarec
studi
hsct
recipi
urti
tori
tract
infect
lrti
well
higher
morinclud
treat
outpati
report
lower
mortal
rate
addit
ent
start
commonli
report
reincreas
diseas
sever
certain
viral
infect
spiratori
virus
includ
rsv
piv
influenza
includ
caus
influenza
viru
b
b
adenoviru
conclud
less
parainfluenza
viru
piv
adenoviru
report
newli
recognis
viral
infect
includalso
associ
increas
risk
rejec
rhinoviru
coronaviru
herpesvirus
exclud
tion
sot
recipi
cytomegaloviru
cmv
human
metapneumoviru
tabl
provid
synopsi
key
earli
diagnosi
respiratori
virus
immupoint
nocompromis
patient
crucial
consider
therapi
effort
limit
spread
respiratori
syncyti
viru
diseas
among
patient
popul
sever
test
option
avail
combin
direct
epidemiolog
dfa
indirect
ifa
fluoresc
antibodi
test
viral
cultur
standard
use
mani
rsv
singlestrand
rna
viru
meminstitut
howev
recent
year
polymeras
ber
paramyxoviru
famili
season
chain
reaction
pcr
gain
popular
given
rsv
outbreak
vari
accord
latitud
temit
increas
sensit
fast
process
time
perat
area
rsv
occur
season
winter
use
often
diagnosi
earli
spring
tropic
subtrop
area
respiratori
syncyti
viru
rsv
influenza
less
season
variat
rsv
outbreak
b
piv
adenoviru
serolog
assay
tropic
may
associ
raini
season
routin
help
detect
acut
infect
rsv
common
caus
communityacquir
note
bacteri
fungal
infect
often
found
respiratori
tract
infect
tendenc
infect
copathogen
along
viral
infect
children
often
adult
almost
children
may
common
piv
primari
infect
age
year
treatment
prevent
respiratori
tract
inwith
sever
diseas
seen
higher
risk
group
fection
vari
depend
pathogen
includ
verylowbirthweight
infant
well
center
diseas
control
prevenchildren
bronchopulmonari
dysplasia
congent
infecti
diseas
societi
america
ital
heart
diseas
immun
defici
rsv
american
societi
blood
marrow
transplani
highli
contagi
reinfect
occur
tation
establish
guidelin
prevent
opportupoint
later
life
result
incomplet
immun
nistic
infect
hsct
recipi
gener
prersv
import
pathogen
immunocomv
guidelin
includ
institut
infectionpromis
patient
mani
observ
studi
control
measur
appropri
hand
hygien
find
commonli
identifi
viral
earli
isol
patient
suspect
respiratori
rti
hsct
sot
recipi
studi
tract
infect
avoid
sick
contact
shown
cumul
incid
rang
across
measur
aim
limit
exposur
hsct
allogen
hsct
recipi
recipi
viral
infect
prevent
autolog
hsct
recipi
measur
includ
vaccin
antivir
paediatr
liver
adult
lung
transplant
laxi
treatment
option
limit
recipi
consid
avail
although
rsv
often
consid
communitythi
articl
review
current
literatur
reacquir
infect
nosocomi
transmiss
also
spiratori
tract
infect
hsct
sot
recipicommon
hospitalacquir
infect
may
occur
sever
reason
hsct
sot
recipi
hsct
patient
rsv
develop
lrti
one
patient
die
rsv
infect
may
difficulti
clear
viru
immunosuppress
state
patient
haematolog
malign
therefor
prolong
period
shed
hsct
recipi
rsv
infect
progress
patient
isol
often
lrti
may
associ
increas
age
place
close
proxim
dedicatlack
rsv
treatment
hsct
recipi
prognosi
also
associ
time
diseas
ed
ward
therefor
opportun
inrel
transplant
patient
infect
prefect
multipl
immunocompromis
patient
engraft
month
posttranspl
tend
environment
contamin
inhav
higher
complic
rate
pneumonia
fect
staff
member
expos
death
peck
colleagu
perform
retropati
taylor
colleagu
report
durspect
studi
follow
hsct
candid
ing
season
ten
case
rsv
diagnos
rsv
urti
pretransplantaat
hsct
unit
bristol
uk
nine
rsv
tion
n
earli
condit
specimen
could
amplifi
restrict
enregimen
n
six
patient
diagnos
earli
zyme
analysi
demonstr
eight
sequenc
condit
regimen
symptom
prior
ident
patient
becom
infect
treatment
delay
virolog
confirmawith
strain
viru
strain
also
diftion
patient
hsct
fere
found
patient
hospitalis
delay
one
progress
proven
rsv
pneuth
commun
suggest
rsv
monia
compar
two
three
patient
nosocomi
acquir
within
hsct
unit
group
delay
hsct
given
findaddit
rsv
season
health
author
recommend
physician
care
provid
may
shed
rsv
figur
inshould
strongli
consid
delay
transplant
creas
commun
outbreak
patient
rsv
infect
perhap
also
factor
nosocomi
transmiss
patient
urti
symptom
even
prior
may
respons
approxim
virolog
confirm
case
rsv
antibodi
titr
tend
low
adult
rsv
typic
begin
urti
major
particularli
immunosuppress
patient
experienc
cough
symptom
therefor
combin
fluoresc
antibodi
may
present
includ
fever
rhinorrhoea
sinu
test
dfa
ifa
viral
cultur
tradicongest
wheez
prognosi
transplant
tional
use
make
diagnosi
rsv
recipi
associ
diseas
sever
process
time
vari
two
test
rewith
develop
lrti
experienc
wors
sult
fluoresc
antibodi
test
avail
outcom
earli
seri
describ
mortal
rate
within
hour
day
contrast
viral
cultur
cell
line
human
epitheli
human
patient
progress
pneumonia
lung
fibroblast
rhesu
monkey
perhap
progress
pneumonia
howevkidney
cell
may
take
sever
week
er
recent
studi
report
lower
mortal
rate
studi
machado
colleagu
past
year
pcr
becom
found
season
commonli
use
pcr
identifi
rsv
patient
lower
viral
level
therefor
may
insuffici
data
human
case
report
sensit
tradit
use
viral
cultur
van
literatur
pregnant
women
treat
elden
colleagu
compar
taqman
ribavirin
latter
half
pregnanc
pcr
versu
viral
cultur
shell
vial
cultur
experi
advers
fetal
outcom
diagnos
rsv
hsct
recipi
taqman
howev
given
concern
pregnant
women
pcr
posit
rsv
sampl
convenshould
tri
avoid
enter
patient
room
tional
cultur
detect
four
case
treatment
aerosolis
product
none
detect
use
shell
vial
cultur
although
definit
trial
evalu
studi
weinberg
colleagu
found
therapeut
role
ribavirin
immunocommultiplex
pcr
sensit
detect
repromis
patient
rsv
trial
variou
dose
spiratori
tract
infect
particularli
rsv
b
treatment
durat
report
piv
lung
transplant
recipi
compar
literatur
hsct
recipi
rsv
pneumonia
viral
cultur
enzym
immunoassay
rapid
shell
lrti
aerosolis
ribavirin
alon
shown
vial
detect
test
pcr
also
associ
signific
benefit
mortal
rate
high
fastest
process
time
hour
rapid
report
literatur
boeckh
coldetect
test
includ
enzymelink
immuleagu
design
randomis
multicentr
trial
nosorb
assay
immunofluoresc
studi
effect
aerosolis
ribavirin
hsct
recipi
rsv
urti
author
report
patient
randomis
receiv
aerosolis
treatment
ribavirin
nonsignific
decreas
rate
antivir
treatment
rsv
controversi
progress
pneumonia
one
nine
patient
conflict
studi
result
found
literatur
ribavirin
group
vs
two
five
patient
ribavirin
guanosin
analogu
main
ancontrol
group
p
lower
viral
tivir
agent
studi
immunocomload
copiesml
reduct
versu
promis
patient
particularli
hsct
recipi
copiesml
increas
p
compar
although
given
oral
intraven
patient
receiv
best
support
care
although
via
inhal
aerosolis
ribavirin
approv
find
intrigu
difficult
make
us
fda
treatment
rsv
aerconclus
given
studi
insuffici
osolis
ribavirin
difficult
administ
repow
result
slow
patient
accrual
quir
small
particl
nebulis
machin
phase
studi
lewinsohn
colleagu
inmay
avail
institut
advers
traven
ribavirin
similar
efficaci
aereffect
includ
psycholog
distress
osolis
ribavirin
howev
also
associ
patient
due
isol
treatment
rash
advers
effect
includ
haemolysi
signifiheadach
conjunct
may
occur
anyon
cant
enough
requir
drug
cessat
two
ten
expos
aerosolis
ribavirin
also
conpati
contrast
glanvil
colleagu
recern
ribavirin
may
teratogen
port
lung
transplant
recipi
rsv
patient
visitor
staff
may
risk
aerwer
treat
combin
intraven
osolis
ribavirin
anim
studi
note
ribavirin
corticosteroid
excel
progincreas
skelet
malform
pregnant
rat
nose
mortal
experienc
mild
hamster
treat
ribavirin
advers
effect
profil
combin
treatment
ribavirin
rsv
tate
process
anoth
import
intervent
intraven
immunoglobulin
ivig
yield
poinvolv
quickli
implement
droplet
contact
tential
encourag
result
mortal
rate
isol
measur
rsv
infect
first
particularli
given
earlier
cours
pect
particularli
given
potenti
respiratori
ill
studi
ghosh
delay
confirm
infect
colleagu
aerosolis
ribavirin
rsv
ivig
diagnost
test
raad
colleagu
administ
bone
marrow
transplant
report
institut
isol
precaut
de
bmt
recipi
rsv
urti
four
patient
creas
rate
rsv
hsct
ward
develop
pneumonia
two
die
rsv
current
avail
rsv
vaccin
ivig
subsequ
discontinu
parainfluenza
viru
wide
replac
monoclon
antibodi
formul
palivizumab
two
phase
studi
boeckh
colleagu
report
long
halfliv
epidemiolog
day
mild
adverseeffect
profil
piv
like
rsv
singlestrand
rna
viru
high
surviv
rate
hsct
recipi
treat
member
paramyxoviru
famili
howevaerosolis
ribavirin
palivizumab
abstract
er
piv
four
differ
serotyp
vari
zamora
colleagu
found
combinapreval
season
clinic
diseas
tion
treatment
aerosolis
ribavirin
either
common
caus
childhood
croup
resultrsv
ivig
palivizumab
ivig
decreas
rate
ing
outbreak
autumn
fall
winter
acut
reject
bronchiol
obliteran
often
associ
adult
taliti
lung
transplant
recipi
pneumonia
diseas
found
yearround
increas
incigiven
avail
inform
swedish
denc
spring
summer
least
consensu
group
propos
aerosolis
commonli
isol
serotyp
ribavirin
rsv
ivig
consid
allogen
well
characteris
hsct
sot
recipi
episod
rejecther
limit
number
studi
evalu
tion
mild
moder
rsv
pneumonia
piv
infect
transplant
recipi
nichol
american
societi
transplant
ast
guidecolleagu
report
hsct
recipi
line
state
patient
upper
respiratori
acquir
piv
infect
tract
diseas
presenc
risk
factor
fred
hutchinson
cancer
research
organ
transplant
recipi
lower
respiracent
period
unlik
rsv
rate
tori
tract
diseas
use
aerosolis
ribavirin
piv
infect
similar
autolog
combin
rsv
immun
globulin
allogen
hsct
recipi
studi
also
palivizumab
consid
report
lung
transplant
recipi
becom
infect
piv
infect
control
method
crucial
prea
studi
nichol
colleagu
report
durvent
respiratori
viral
infect
includ
ing
season
hsct
recipi
rsv
rsv
transmit
via
aerosolis
fred
hutchinson
cancer
research
center
acquir
droplet
fomit
hand
hygien
import
piv
approxim
case
occur
paand
effect
prevent
measur
mani
hospit
tient
seen
outpati
clinic
increas
numoff
alcoholbas
handwash
product
facilib
case
identifi
hospit
septemb
octob
suggest
outbreak
dfa
ifa
viral
cultur
use
primari
monkey
even
though
increas
piv
infect
kidney
tissu
pcr
adult
tend
shed
commun
molecular
analysi
demonstr
low
titr
piv
emphasi
mani
isol
relat
fell
find
sensit
detect
method
name
distinct
cluster
suggest
mani
piv
pcr
studi
weinberg
colleagu
found
case
occur
via
nosocomi
transmiss
pcr
fact
sensit
detect
piv
outpati
set
serotyp
piv
common
caus
communityacquir
although
vitro
studi
shown
respiratori
ill
children
progress
ribavirin
activ
piv
clinic
studi
lrti
time
immunocompet
yield
mix
result
smaller
studi
adult
often
develop
incomplet
immuhsct
recipi
seem
suggest
aerosolis
niti
infect
restrict
upper
respiratori
intraven
ribavirin
result
decreas
mortract
tend
mild
taliti
rate
compar
histor
control
past
sever
year
studi
demonlarg
seri
use
ribavirin
without
ivig
strate
piv
associ
signific
morhowev
shown
efficaci
biditi
mortal
transplant
recipi
imnichol
colleagu
also
report
munocompromis
patient
piv
may
initi
preribavirin
affect
durat
viral
shedsent
urti
patient
ding
review
avail
inform
cough
symptom
includ
rhinorrhoea
ast
guidelin
state
therawheez
coryza
fever
less
common
peutic
option
current
avail
consider
approxim
onethird
hsct
recipi
given
use
aerosolis
ribavirin
piv
progress
lrti
highrisk
patient
pivassoci
sever
lower
literatur
cite
mortal
rate
rang
tract
diseas
care
attent
diagnosi
corticosteroid
administr
treatment
bacteri
fungal
coinfect
also
graftversushost
diseas
believ
risk
import
factor
pneumonia
lung
transplant
recipi
piv
infect
involv
lower
prevent
respiratori
tract
piv
infect
predispos
transplant
recipi
rsv
infect
control
measur
coinfect
bacteri
fungal
pathoimport
prevent
spread
piv
among
gen
studi
report
hsct
transplant
recipi
inocul
occur
recipi
piv
superimpos
bacteri
direct
contact
fomit
infect
fungal
pneumonia
piv
also
associatobject
proper
hand
hygien
essenti
cone
higher
rate
bronchiol
obliteran
tact
droplet
precaut
also
institut
allograft
reject
lung
transplant
recipi
earli
viral
infect
first
suspect
import
note
immunocompromis
patient
diagnosi
may
prolong
shed
durat
demondiagnost
method
piv
similar
strate
one
report
two
hsct
recipi
rsv
includ
fluoresc
antibodi
test
shed
piv
day
formalininactiv
piv
vaccin
availastudi
conduct
period
report
ble
vaccin
result
antibodi
rether
anywher
case
influenza
spons
shown
prevent
personyear
liver
transplant
recipi
tion
studi
current
underway
evalu
personyear
lung
transplant
reth
efficaci
intranas
piv
vaccin
immucipi
viral
shed
occur
day
nocompet
patient
immunocompet
patient
longer
durat
shed
occasion
note
influenza
ed
patient
nichol
colleagu
report
mean
durat
influenza
viru
shed
epidemiolog
allogen
hsct
recipi
day
rang
day
patient
receiv
treatment
influenza
viru
singlestrand
neg
shed
longer
period
averag
day
sens
rna
viru
member
orthomyxoviru
famili
three
type
influenza
b
case
report
note
shed
influenza
viru
c
base
antigen
differ
influenza
year
research
need
deterhighli
infecti
spread
respiratori
dropmin
frequenc
signific
prolong
let
epidem
typic
occur
winter
shed
transplant
recipi
month
result
signific
morbid
mortal
machado
colleagu
report
influenza
case
occur
summer
month
tropic
climat
although
given
known
patient
infect
influenza
develop
potenti
prolong
shed
limit
typic
symptom
fever
headach
myalabl
detect
virus
studi
gia
symptom
may
less
common
complet
clear
repres
true
incid
transplant
patient
popul
although
pacas
influenza
within
singl
influenza
season
case
major
strain
alper
report
method
gather
detail
sympthough
minor
strain
may
also
caus
diseas
tom
prospect
patient
inhowev
antigen
chang
viru
vaccin
fluenza
viru
recov
asymptomat
eg
content
popul
vaccin
penetr
lung
transplant
patient
undergo
routin
bronantivir
use
resist
lead
differ
circuchoscopi
signific
find
late
influenza
strain
year
sever
articl
unclear
gener
influenza
suspect
note
infect
transplant
patient
patient
present
constel
either
influenza
b
unclear
fever
rhinorrhoea
cough
malais
myalgia
andor
small
seri
whether
substant
differheadach
winter
season
progress
enc
clinic
present
outcom
although
urti
pneumonia
rare
immunocominfluenza
commonli
consid
communitypet
patient
may
underestim
imacquir
respiratori
ill
nosocomi
spread
also
munocompromis
patient
certain
complicaoccur
hospitalis
hsct
sot
recipi
may
tion
common
bmt
sot
recipi
becom
infect
soon
transplant
result
includ
bacteri
superinfect
cn
inin
sever
diseas
wors
prognosi
volvement
myocard
graft
dysfunct
incid
influenza
sot
recipi
reject
vari
depend
type
transplant
durat
prescrib
immunocompet
individu
although
infrequ
resist
nasopharyng
throat
specimen
bronoseltamivir
report
literatur
choalveolar
lavag
endotrach
aspir
machado
colleagu
report
systemb
use
diagnosi
influenza
gold
atic
approach
use
oseltamivir
treat
earli
influstandard
viral
cultur
process
time
enza
infect
bmt
recipi
progress
day
test
includ
fluoresc
antipneumonia
observ
patient
similar
bodi
techniqu
dfa
ifa
also
avail
seri
although
notabl
fact
viral
load
highest
first
mani
patient
seri
especi
high
day
ill
quickli
decreas
afterrisk
earli
postbmt
period
therefor
ward
diagnosi
easier
earlier
cours
vaccin
ill
pcr
test
avail
becom
ribavirin
anoth
antivir
agent
commonli
use
institut
diagnos
mention
literatur
small
studi
respiratori
virus
includ
influenza
b
shown
vitro
activ
influenza
anecdot
report
suggest
possibl
activ
treatment
compet
patient
expert
suggest
ad
aerosolis
ribavirin
neuraminidas
inhibitor
two
class
antivir
medic
exist
therapi
transplant
recipi
sever
influenprevent
treatment
influenza
infect
za
infect
inhibitor
adamantan
amantadin
rimantadin
activ
influenza
neuraminidas
inhibitor
oseltamivir
zanamivir
activ
influcar
hand
hygien
avoid
sick
contact
enza
b
past
sever
year
yearli
vaccin
main
prevent
worldwid
increas
adamantaneresist
measur
influenza
transplant
recipi
influenza
viru
us
influenza
close
contact
healthcar
worker
viru
adamantan
resist
result
receiv
standard
inactiv
vaccin
intrain
guidelin
chang
advisori
commuscularli
live
attenu
intranas
vaccin
mitte
immunis
practic
state
recommend
patient
popul
transamantadin
rimantadin
use
plant
recipi
may
develop
weaker
antibodi
retreat
chemoprophylaxi
influenza
spons
vaccin
compar
immunocomu
petent
individu
frequenc
protect
oseltamivir
zanamivir
two
neurespons
rang
wide
varaminidas
inhibitor
current
avail
rie
transplant
popul
probabl
also
treatment
oseltamivir
administ
oraldepend
individu
factor
eg
type
ly
zanamivir
inhal
abl
intens
immunosuppress
time
transshorten
durat
ill
day
immupl
vaccin
factor
eg
immunogen
nocompet
patient
given
within
hour
particular
vaccin
strain
correl
vacsymptom
develop
although
pauciti
cine
strain
epidem
strain
given
mani
data
transplant
recipi
expert
includpati
achiev
protect
antibodi
respons
ing
ast
recommend
treat
hsct
sot
annual
variabl
respons
rate
recipi
influenza
use
dose
predict
yearli
vaccin
encourag
current
recommend
plant
recipi
may
suscept
monitor
vaccin
titr
also
unclear
whether
pandem
influenza
given
immunocomther
role
higher
dose
repeat
vaccinapromis
state
well
frequent
exposur
tion
hsct
sot
recipi
increas
protecth
healthcar
system
infect
transplant
pativ
immun
tient
may
prone
sever
diseas
higher
rate
complic
patient
may
prevent
antivir
medic
may
conalso
difficulti
clear
viru
could
sider
patient
respond
becom
superspread
concern
chanc
respond
vaccin
sever
acut
respiratori
syndrom
sar
unabl
receiv
vaccin
pandem
influenza
would
also
like
affect
unclear
whether
strategi
employ
transplant
centr
similar
sar
outbreak
full
cours
influenza
season
pandem
influenza
may
lead
close
transpostexposur
manner
plant
centr
period
time
prompt
consider
least
temporari
revis
pandem
influenza
tation
guidelin
eg
donor
recipi
screeninfluenza
result
three
centuri
ing
pandem
highest
avian
influenza
inher
resist
adamort
associ
spanish
flu
mantan
neuraminidas
inhibitor
use
pandem
result
million
death
patient
avian
influenza
current
concern
avian
influenza
demonstr
efficaci
start
earli
could
progress
becom
next
pandemhowev
oseltamivirresist
virus
ic
first
case
avian
influenza
report
identifi
patient
improv
poultri
outbreak
hong
kong
treatment
vaccin
current
follow
human
case
human
case
occur
via
birdtohuman
transmiss
although
specul
adenoviru
may
acquir
persontoperson
may
limit
humantohuman
transmistransmiss
primari
rti
howev
ades
human
case
avian
influenza
noviru
diseas
immunocompromis
patient
associ
high
mortal
rate
particumay
repres
reactiv
latent
infect
larli
younger
patient
abl
mount
addit
adenoviru
infect
produc
varieti
signific
immunolog
respons
clinic
syndrom
addit
respiratori
tract
ill
pattern
ill
may
vari
date
case
avian
host
transplant
type
adenoviru
serotyp
influenza
transplant
recipi
howev
given
heighten
concern
expert
extrapol
adenoviru
infect
account
viral
inform
known
respiratori
virti
recent
larg
case
seri
ruse
transplant
recipi
address
implicamor
common
children
adenoviru
tion
possibl
pandem
influenza
populath
least
commonli
report
common
respir
patient
level
possibl
transtori
virus
seri
test
patient
symptomat
urti
true
incid
adegold
standard
identif
adenoviru
infecnoviru
infect
would
probabl
higher
pation
tient
clinic
manifest
test
use
caution
transplant
recipi
posit
test
lower
respiratori
tract
samwho
increas
risk
renal
impair
ple
patient
mortal
may
result
final
two
recent
articl
question
need
involv
digest
system
kidney
treatment
patient
document
adeor
cn
outcom
adenoviru
rti
noviru
infect
make
watch
wait
reahsct
poor
cumul
mortal
sonabl
option
minim
symptomat
paof
case
onethird
tient
death
occur
patient
adenoviru
urti
without
evid
pneumonia
studi
address
potenti
overal
incid
sever
longitudin
role
rhinovirus
ubiquit
common
cold
studi
review
potenti
signific
pathogen
respiratori
pathogen
sot
adenoviru
infect
lung
transplant
patient
hsct
recipi
aggreg
suggest
demonstr
incid
hyrhinoviru
infect
may
underdiagnos
four
pothesis
adenoviru
rti
may
prerec
studi
prospect
activ
surveildispos
acut
chronic
reject
lung
translanc
newer
diagnost
techniqu
note
rhiplant
recipi
data
support
hypothenoviru
infect
cohort
two
progress
lrti
observ
test
insensit
miss
case
two
death
rhinoviru
pneucas
emerg
pcr
assay
may
provid
monia
note
children
may
particularli
easier
faster
diagnosi
viral
cultur
remain
suscept
rhinoviru
one
seri
note
mortal
postbmt
patient
rhinoviru
tine
antivir
prophylaxi
especi
rare
patient
underw
bmt
primari
immupathogen
first
sever
posttranspl
nodefici
therefor
may
repres
month
vzv
may
occur
time
posttranspl
uniqu
suscept
popul
mani
older
dfa
dormant
viru
ubiquit
popul
ifa
panel
includ
rhinoviru
routin
sinc
case
vzv
pneumonia
hsct
test
newer
diagnost
technolog
ie
sot
recipi
preced
characterist
pcr
becom
wide
use
true
epidemiolvesicular
skin
rash
sinc
vzv
pneumonia
ogi
impact
rhinoviru
infect
hsct
rare
presum
prompt
antivir
thersot
recipi
becom
clearer
present
api
aciclovir
halt
progress
reactither
specif
antivir
therapi
avail
vation
diseas
pneumonia
patient
antecetreat
rhinoviru
infect
dent
herp
zoster
follow
pneumonia
also
empir
treat
bacteri
superinfec
tion
given
high
rate
superinfect
aggress
natur
common
coronavirus
like
rhinovirus
frequent
pathogen
like
staphylococcu
aureu
caus
benign
urti
occur
annual
winter
role
human
herpesviru
hhv
time
commun
outbreak
systemat
studi
pulmonari
pathogen
remain
poorli
untheir
possibl
role
lrti
hsct
sot
recipiderstood
activ
replic
either
ent
undertaken
recent
experi
viru
may
detect
transplant
recipi
sar
coronavirus
caus
agent
sar
particularli
hsct
patient
consist
pattern
noteworthi
studi
tissu
obtain
autopsi
pulmonari
diseas
associ
eifrom
liver
transplant
recipi
reveal
extrem
ther
viru
propos
associ
includ
pneumonia
high
number
viral
copi
suggest
bronchiol
obliteran
without
organisreason
fatal
cours
well
possibl
ing
pneumonia
commonli
accept
treatrol
immunosuppress
patient
super
avail
either
viru
though
spreader
epidem
agent
activ
herpesvirus
eg
widespread
avail
pcr
diagnost
ganciclovir
cidofovir
vitro
activ
coronavirus
research
need
clarifi
virus
frequenc
incid
infect
transplant
recipi
newli
recognis
pathogen
human
metapnearli
virus
herpesviru
famili
neumoviru
hmpv
first
recov
report
occasion
caus
pneumonia
cohort
dutch
children
rti
hsct
sot
recipi
cytomegaloviru
short
time
sinc
report
number
import
cmv
perhap
import
posttranssurvey
demonstr
common
plant
pathogen
occasion
caus
respiratoand
potenti
signific
pathogen
transri
infect
pathophysiolog
epidemiolog
plant
patient
three
studi
examin
frequenand
treatment
beyond
scope
review
cy
hmpv
recoveri
store
bronchoalveolar
herp
simplex
viru
type
varicella
lavag
specimen
document
posit
rate
zoster
viru
vzv
rare
report
among
transplant
recipi
symptomatpotenti
pulmonari
pathogen
era
rouic
rti
rate
may
seem
low
compar
observ
rate
rsv
piv
influen
